Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Demeure

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Clinical Genetics|October 5, 2022
Six case reports of NTHL1-associated tumor syndrome further support it as a multi-tumor predisposition syndromeChelsey B Weatherill, Sarah A Burke, Carolyn G Haskins, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|September 8, 2007
End-of-procedure cefazolin concentrations after administration for prevention of surgical-site infectionErin Koopman, David E Nix, Brian L Erstad, et al.
Diagnostics (Basel, Switzerland)|March 11, 2023
Can Imaging Using Radiomics and Fat Fraction Analysis Detect Early Tissue Changes on Historical CT Scans in the Regions of the Pancreas Gland That Subsequently Develop Adenocarcinoma?Ronald Lee Korn, Andre Burkett, Jeff Geschwind, et al.
World Journal of Surgery|January 18, 2025
Loss of O6-Methylguanine-DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine NeoplasmsMark G Evans, Joanne Xiu, Sourat Darabi, et al.
Molecular Cancer Therapeutics|February 19, 2008
Adrenocortical carcinoma survival rates correlated to genomic copy number variantsElizabeth A Stephan, Tae-Hoon Chung, Clive S Grant, et al.
Surgery|November 19, 2013
PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic targetMichael J Demeure, Kathryn E Coan, Clive S Grant, et al.
Plos One|March 11, 2016
Pathway Implications of Aberrant Global Methylation in Adrenocortical CancerChristophe R Legendre, Michael J Demeure, Timothy G Whitsett, et al.
The Journal of Clinical Endocrinology and Metabolism|June 29, 2024
A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid CarcinomaKartik Sehgal, Anthony Serritella, Mofei Liu, et al.
Journal of the American College of Surgeons|April 23, 2024
Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted TherapySourat Darabi, Tolulope Adeyelu, Andrew Elliott, et al.
Journal of Proteome Research|December 17, 2013
Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysisMindy Porterfield, Peng Zhao, Haiyong Han, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Clinical Genetics|October 5, 2022
Six case reports of NTHL1-associated tumor syndrome further support it as a multi-tumor predisposition syndromeChelsey B Weatherill, Sarah A Burke, Carolyn G Haskins, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|September 8, 2007
End-of-procedure cefazolin concentrations after administration for prevention of surgical-site infectionErin Koopman, David E Nix, Brian L Erstad, et al.
Diagnostics (Basel, Switzerland)|March 11, 2023
Can Imaging Using Radiomics and Fat Fraction Analysis Detect Early Tissue Changes on Historical CT Scans in the Regions of the Pancreas Gland That Subsequently Develop Adenocarcinoma?Ronald Lee Korn, Andre Burkett, Jeff Geschwind, et al.
World Journal of Surgery|January 18, 2025
Loss of O6-Methylguanine-DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine NeoplasmsMark G Evans, Joanne Xiu, Sourat Darabi, et al.
Molecular Cancer Therapeutics|February 19, 2008
Adrenocortical carcinoma survival rates correlated to genomic copy number variantsElizabeth A Stephan, Tae-Hoon Chung, Clive S Grant, et al.
Surgery|November 19, 2013
PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic targetMichael J Demeure, Kathryn E Coan, Clive S Grant, et al.
Plos One|March 11, 2016
Pathway Implications of Aberrant Global Methylation in Adrenocortical CancerChristophe R Legendre, Michael J Demeure, Timothy G Whitsett, et al.
The Journal of Clinical Endocrinology and Metabolism|June 29, 2024
A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid CarcinomaKartik Sehgal, Anthony Serritella, Mofei Liu, et al.
Journal of the American College of Surgeons|April 23, 2024
Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted TherapySourat Darabi, Tolulope Adeyelu, Andrew Elliott, et al.
Journal of Proteome Research|December 17, 2013
Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysisMindy Porterfield, Peng Zhao, Haiyong Han, et al.
Pageof 8